Veeva Systems Inc. (NYSE:VEEV) SVP Sells $746,297.16 in Stock

Veeva Systems Inc. (NYSE:VEEV) SVP Jonathan Faddis sold 3,598 shares of the firm’s stock in a transaction dated Monday, April 15th. The stock was sold at an average price of $207.42, for a total value of $746,297.16. Following the completion of the transaction, the senior vice president now owns 10,668 shares of the company’s stock, valued at $2,212,756.56. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Veeva Systems Price Performance

Shares of NYSE:VEEV opened at $198.37 on Friday. The business’s 50 day moving average price is $221.17 and its 200-day moving average price is $202.80. The firm has a market capitalization of $32.00 billion, a PE ratio of 61.61, a P/E/G ratio of 2.01 and a beta of 0.74. Veeva Systems Inc. has a 1 year low of $160.21 and a 1 year high of $236.90.

Veeva Systems (NYSE:VEEV) last issued its quarterly earnings results on Thursday, February 29th. The technology company reported $0.92 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.81 by $0.11. The firm had revenue of $630.62 million for the quarter, compared to analyst estimates of $620.75 million. Veeva Systems had a return on equity of 11.26% and a net margin of 22.24%. As a group, analysts expect that Veeva Systems Inc. will post 4.11 earnings per share for the current year.

Analyst Ratings Changes

VEEV has been the subject of several recent research reports. Citigroup lifted their price target on Veeva Systems from $240.00 to $264.00 and gave the company a “buy” rating in a research report on Friday, March 1st. Piper Sandler lifted their price target on Veeva Systems from $220.00 to $245.00 and gave the company an “overweight” rating in a research report on Friday, March 1st. Barclays lifted their price target on Veeva Systems from $240.00 to $245.00 and gave the company an “overweight” rating in a research report on Friday, March 1st. Stifel Nicolaus lifted their price target on Veeva Systems from $205.00 to $250.00 and gave the company a “buy” rating in a research report on Friday, March 1st. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $250.00 price target on shares of Veeva Systems in a research report on Wednesday, March 27th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and fifteen have issued a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $234.90.

Institutional Trading of Veeva Systems

A number of institutional investors have recently made changes to their positions in VEEV. MetLife Investment Management LLC acquired a new stake in shares of Veeva Systems in the first quarter worth approximately $1,906,000. Dimensional Fund Advisors LP boosted its stake in Veeva Systems by 1.8% during the first quarter. Dimensional Fund Advisors LP now owns 190,289 shares of the technology company’s stock worth $40,430,000 after buying an additional 3,286 shares during the last quarter. Sequoia Financial Advisors LLC boosted its stake in Veeva Systems by 11.5% during the first quarter. Sequoia Financial Advisors LLC now owns 1,018 shares of the technology company’s stock worth $216,000 after buying an additional 105 shares during the last quarter. National Pension Service boosted its stake in Veeva Systems by 3.0% during the first quarter. National Pension Service now owns 195,170 shares of the technology company’s stock worth $41,466,000 after buying an additional 5,607 shares during the last quarter. Finally, Vanguard Group Inc. boosted its stake in Veeva Systems by 1.0% during the first quarter. Vanguard Group Inc. now owns 12,888,204 shares of the technology company’s stock worth $2,738,229,000 after buying an additional 132,560 shares during the last quarter. 88.20% of the stock is owned by institutional investors and hedge funds.

Veeva Systems Company Profile

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States.